Kiniksa Pharmaceuticals International, plc
KNSA
Kedudukan dalam Saham
#2912
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Harga Saham
$82.30
Modal Pasaran
$6.42B
Perubahan (1 hari)
3.55%
Perubahan (1 tahun)
111.08%
Negara
GB
Perdagangan Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Sejarah pecahan saham untuk Kiniksa Pharmaceuticals International, plc (KNSA)
Saham Kiniksa Pharmaceuticals International, plc (simbol: KNSA) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham KNSA yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham KNSA.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham KNSA yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham KNSA.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 0 | - |
US
|
|
| 0 | - |
SE
|
|
| 0 | - |
FR
|
|
| 0 | - |
IT
|
|
| 0 | - |
US
|
